East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Pantoprazole Sodium for Delayed-Release Oral Suspension, 40 mg. Aurobindo Pharma’s Pantoprazole Sodium for Delayed-Release Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Protonix for Delayed-Release Oral Suspension manufactured by Wyeth Pharmaceuticals LLC.

Pantoprazole Sodium for Delayed-Release Oral Suspension are indicated for the:

• Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD)
• Maintenance of Healing of Erosive Esophagitis
• Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome.